Michael A. Metzger
Chief Executive Officer and Director
Michael A. Metzger has served as our Chief Executive Officer since February 2022 and previously served as our President and Chief Operating Officer since May 2015 and as a member of our board of directors since July 2019.
Michael was President & COO from December 2013 to October 2014 and President, CEO and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded biotechnology company, from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Michael served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a publicly traded company focused on the development of ADCs for oncology, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Michael served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., a venture capital firm. Michael recently served on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company which was acquired by SOBI AB in 2023, as well as the boards of other private and not-for-profit companies.
Michael received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.
Michael was President & COO from December 2013 to October 2014 and President, CEO and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded biotechnology company, from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Michael served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a publicly traded company focused on the development of ADCs for oncology, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Michael served as Vice President Corporate Development at Onconova Therapeutics, Inc. and was a Managing Director at MESA Partners, Inc., a venture capital firm. Michael recently served on the board of CTI Biopharma Corp., a publicly traded biopharmaceutical company which was acquired by SOBI AB in 2023, as well as the boards of other private and not-for-profit companies.
Michael received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.